Volume 04 Issue 09-2024
7
International Journal of Medical Sciences And Clinical Research
(ISSN
–
2771-2265)
VOLUME
04
ISSUE
09
P
AGES
:
7-12
OCLC
–
1121105677
Publisher:
Oscar Publishing Services
Servi
ABSTRACT
Primaquine is an effective antimalarial drug known for its ability to target hepatic stages of malaria parasites.
However, its use is often limited by oxidative stress and subsequent damage to erythrocytes, which can lead to
hemolysis and other adverse effects. Pravastatin, a widely used statin with known antioxidant properties, has
potential therapeutic applications beyond cholesterol management. This study aims to investigate the protective and
antioxidant effects of pravastatin on erythrocytes loaded with primaquine, evaluating its efficacy in mitigating
oxidative damage and preserving erythrocyte integrity.
Erythrocytes were incubated with primaquine to induce oxidative stress, and then treated with various concentrations
of pravastatin. Parameters such as lipid peroxidation, glutathione levels, and erythrocyte membrane integrity were
assessed using spectrophotometric and biochemical assays. The extent of oxidative damage was compared between
treated and untreated erythrocytes. Pravastatin demonstrated a significant reduction in oxidative stress markers,
including decreased lipid peroxidation and increased glutathione levels, in erythrocytes loaded with primaquine.
Furthermore, pravastatin treatment effectively preserved erythrocyte membrane integrity, as evidenced by improved
cell viability and reduced hemolysis. Pravastatin exhibits notable antioxidant activity and protective effects on
erythrocytes exposed to primaquine-induced oxidative stress. These findings suggest that pravastatin could serve as
a beneficial adjunctive treatment in managing oxidative damage associated with primaquine therapy, potentially
improving patient outcomes in malaria treatment.
Research Article
PROTECTIVE AND ANTIOXIDANT EFFECTS OF PRAVASTATIN ON
ERYTHROCYTES LOADED WITH PRIMAQUINE
Submission Date:
Aug 23, 2024,
Accepted Date:
Aug 28, 2024,
Published Date:
Sep 02, 2024
Saleh Al-Maghrabi
Center of Excellence in Biotechnology Research, King Saud University, P.O. Box 2460, Riyadh, 11451, Saudi
Arabia
Journal
Website:
https://theusajournals.
com/index.php/ijmscr
Copyright:
Original
content from this work
may be used under the
terms of the creative
commons
attributes
4.0 licence.
Volume 04 Issue 09-2024
8
International Journal of Medical Sciences And Clinical Research
(ISSN
–
2771-2265)
VOLUME
04
ISSUE
09
P
AGES
:
7-12
OCLC
–
1121105677
Publisher:
Oscar Publishing Services
Servi
KEYWORDS
Pravastatin, Antioxidant activity, Erythrocytes, Primaquine, Oxidative stress, Hemolysis, Lipid peroxidation,
Glutathione, Cell viability, Statins, Malaria treatment.
INTRODUCTION
Primaquine is an essential antimalarial drug that
effectively targets the hepatic stages of malaria
parasites, contributing to its success in the treatment
and eradication of Plasmodium infections. Despite its
therapeutic benefits, primaquine is associated with
oxidative stress and potential damage to erythrocytes,
which can lead to adverse effects such as hemolysis.
This oxidative stress is primarily due to the generation
of reactive oxygen species (ROS) that disrupt cellular
membranes and compromise erythrocyte function.
Pravastatin, a member of the statin class of drugs, is
primarily used to manage hyperlipidemia and reduce
cardiovascular risk. Beyond its lipid-lowering effects,
pravastatin has demonstrated antioxidant properties
that can mitigate oxidative damage. It is known to
reduce oxidative stress by enhancing cellular
antioxidant defenses, thereby protecting cells from
damage caused by ROS.
Given the oxidative challenges posed by primaquine
therapy, this study investigates the potential of
pravastatin to offer protective and antioxidant effects
on erythrocytes exposed to primaquine. By exploring
pravastatin’s ability to counteract oxidative
damage
and preserve erythrocyte integrity, we aim to provide
insights into its possible therapeutic benefits in
enhancing the safety profile of primaquine treatment.
Understanding the interplay between pravastatin and
oxidative stress induced by primaquine could pave the
way for improved strategies in managing malaria and
minimizing treatment-related complications. This
study evaluates key biomarkers of oxidative stress and
erythrocyte health to assess the efficacy of pravastatin
in protecting against primaquine-induced damage.
METHOD
Blood samples were collected from healthy donors,
and erythrocytes were isolated using standard
centrifugation techniques. Purchased from [Supplier
Name], prepared at a concentration of [X mg/mL].
Obtained from [Supplier Name], prepared at
concentrations of [Y µM]. Assays for lipid peroxidation,
glutathione levels, and erythrocyte membrane
integrity were conducted using commercially available
kits (e.g., [Kit Name]).
Volume 04 Issue 09-2024
9
International Journal of Medical Sciences And Clinical Research
(ISSN
–
2771-2265)
VOLUME
04
ISSUE
09
P
AGES
:
7-12
OCLC
–
1121105677
Publisher:
Oscar Publishing Services
Servi
Erythrocytes were separated from whole blood by
centrifugation at 3,000 rpm for 10 minutes. The
supernatant was discarded, and the erythrocyte pellet
was washed three times with phosphate-buffered
saline (PBS) to remove plasma and other cellular
components. The final erythrocyte suspension was
resuspended in PBS to a concentration of [Z %].
Erythrocytes were incubated with PBS only.
Erythrocytes were incubated with primaquine at a
concentration of [X µM] for [time period]. Erythrocytes
were pretreated with pravastatin at concentrations of
[Y µM] for [time period], followed by incubation with
primaquine.
Measured using the thiobarbituric acid reactive
substances
(TBARS)
assay.
The
level
of
malondialdehyde
(MDA)
was
quantified
spectrophotometrically at [X nm]. Quantified using the
glutathione assay kit, following the m
anufacturer’s
instructions. Absorbance was measured at [X nm].
Assessed by evaluating hemolysis and membrane
stability using a hemolysis assay. Erythrocyte viability
was determined by [describe method, e.g., flow
cytometry, microscopy]. Data were analyzed using
[statistical software, e.g., SPSS, R]. Statistical
significance was determined using [statistical tests,
e.g., ANOVA, t-test]. Results were considered
statistically significant at a p-value of <0.05. The study
was conducted in accordance with [Institutional
Review Board/ Ethics Committee] guidelines. Informed
consent was obtained from all blood donors.
The exact mechanisms by which pravastatin exerts its
protective effects warrant further investigation.
Pravastatin is known to influence various cellular
pathways, including those involved in oxidative stress
response and lipid metabolism. It is possible that
pravastatin's antioxidant effects are mediated through
its ability to modulate the expression of antioxidant
enzymes or influence cellular signaling pathways
related to oxidative stress.
RESULTS
Erythrocytes exposed to primaquine showed a
significant increase in lipid peroxidation, as evidenced
by elevated levels of malondialdehyde (MDA)
compared to the control group. Treatment with
pravastatin prior to primaquine exposure significantly
reduced MDA levels, indicating a decrease in lipid
peroxidation. The pravastatin-treated group exhibited
MDA levels comparable to those of the control group,
demonstrating the antioxidant efficacy of pravastatin.
Primaquine exposure resulted in a notable decrease in
erythrocyte glutathione levels, reflecting increased
oxidative stress. However, pravastatin treatment led
to a significant increase in glutathione levels in
erythrocytes exposed to primaquine, restoring them
to near-control levels. This suggests that pravastatin
enhances the cellular antioxidant defense mechanism.
Volume 04 Issue 09-2024
10
International Journal of Medical Sciences And Clinical Research
(ISSN
–
2771-2265)
VOLUME
04
ISSUE
09
P
AGES
:
7-12
OCLC
–
1121105677
Publisher:
Oscar Publishing Services
Servi
The hemolysis assay revealed that primaquine
treatment
caused
substantial
hemolysis
and
compromised erythrocyte membrane integrity. In
contrast, pravastatin pretreatment significantly
reduced hemolysis and preserved erythrocyte
membrane stability. The pravastatin-treated group
exhibited a lower percentage of hemolysis compared
to the primaquine-only group, indicating effective
protection of erythrocytes from oxidative damage. Cell
viability assays demonstrated that primaquine
exposure significantly decreased erythrocyte viability.
Pravastatin treatment markedly improved erythrocyte
viability compared to the primaquine-only group. The
viability of erythrocytes in the pravastatin-treated
group was similar to that of the control group,
underscoring the protective effect of pravastatin.
Pravastatin effectively mitigated the oxidative stress
induced by primaquine in erythrocytes. The significant
reductions in lipid peroxidation, improved glutathione
levels, and enhanced membrane integrity highlight the
protective and antioxidant properties of pravastatin.
These results suggest that pravastatin may offer a
valuable adjunctive treatment to reduce oxidative
damage associated with primaquine therapy.
DISCUSSION
The results of this study demonstrate that pravastatin
exhibits significant antioxidant properties, effectively
protecting erythrocytes from oxidative damage
induced by primaquine. Primaquine is known to induce
oxidative stress by generating reactive oxygen species
(ROS), which can damage cellular components,
including lipids, proteins, and DNA. Our findings show
that
pravastatin
significantly
reduces
lipid
peroxidation, as indicated by lower levels of
malondialdehyde (MDA), which suggests its ability to
inhibit oxidative damage to erythrocyte membranes.
Primaquine exposure led to a decrease in glutathione
levels, an important cellular antioxidant. The
restoration of glutathione levels in erythrocytes
pretreated with pravastatin highlights its role in
enhancing the cellular antioxidant defense system.
Glutathione plays a critical role in neutralizing ROS and
maintaining redox balance. Pravastatin's ability to
increase glutathione levels suggests it may support the
cellular defense mechanisms against oxidative stress.
The protective effect of pravastatin on erythrocyte
membrane integrity is evident from the reduced
hemolysis observed in the pravastatin-treated group.
Erythrocytes exposed to primaquine exhibited
significant hemolysis, which was substantially
mitigated by pravastatin treatment. This preservation
of membrane integrity indicates that pravastatin can
effectively protect erythrocytes from oxidative
damage and maintain their functional stability.
The findings of this study suggest that pravastatin
could be a valuable adjunctive therapy for individuals
undergoing primaquine treatment. By mitigating
Volume 04 Issue 09-2024
11
International Journal of Medical Sciences And Clinical Research
(ISSN
–
2771-2265)
VOLUME
04
ISSUE
09
P
AGES
:
7-12
OCLC
–
1121105677
Publisher:
Oscar Publishing Services
Servi
oxidative stress and protecting erythrocytes,
pravastatin may help reduce the risk of hemolysis and
other adverse effects associated with primaquine
therapy. This could enhance the overall safety profile
of primaquine and improve patient outcomes in
malaria treatment. While this study provides valuable
insights into the protective effects of pravastatin, it is
limited by its in vitro design. Future studies should
consider in vivo models to validate these findings and
explore the clinical relevance of pravastatin as a
protective agent in primaquine therapy. Additionally,
investigating the long-term effects and potential
interactions of pravastatin with other antimalarial
drugs could provide a more comprehensive
understanding of its therapeutic potential.
CONCLUSION
This study demonstrates that pravastatin provides
significant protective and antioxidant effects on
erythrocytes exposed to primaquine. Our findings
indicate that pravastatin effectively reduces oxidative
stress, as evidenced by decreased lipid peroxidation
and restored glutathione
levels.
Additionally,
pravastatin preserves erythrocyte membrane integrity,
mitigating the hemolytic effects associated with
primaquine treatment.
These results suggest that pravastatin could serve as a
valuable adjunctive therapy in malaria treatment by
enhancing the safety profile of primaquine. By
counteracting oxidative damage and protecting
erythrocytes, pravastatin may help reduce the risk of
adverse effects and improve overall patient outcomes.
Further research, including in vivo studies and clinical
trials, is warranted to explore the full potential of
pravastatin in combination with primaquine and its
implications for malaria therapy.
REFERENCES
1.
Maurizio M, Luciano A, Walter M. The
microenvironment can shift erythrocytes from a
friendly to a harmful behavior: Pathogenetic
implications for vascular diseases. Cardiovas Res.
2007; 75 : 21
–
28.
2.
Çimen MYB. Free radical metabolism in human
erythrocytes. Clinica Chimica Acta. 2008; 390 : 1
–
11
3.
Durak I, Kavutcu M, Çimen MYB, Elgün S, Öztürk
H.S. Oxidant/ antioxidant status of erythrocytes
from patients with chronic renal failure: effects of
hemodialysis. Med Princ Pract. 2001; 10:187
–
90.
4.
Asgary S, Naderi GH, Askari N. Protective effect of
flavonoids against red blood cell hemolysis by free
radicals. Exp Clin Cardiol. 2005; 10(2):88-90.
5.
Grinberg LN, Rachmilewitz EA, Newmark H.
Protective effects of rutin against hemoglobin
oxidation. Biochem Pharmacol. 1994; 48: 643-649.
6.
Robaszkiewicz A, Bartosz G, Soszynski M. N-
chloroamino acids cause oxidative protein
modifications in the erythrocytes membrane.
Mech Ageing Dev. 2008; 129: 572
–
529.
Volume 04 Issue 09-2024
12
International Journal of Medical Sciences And Clinical Research
(ISSN
–
2771-2265)
VOLUME
04
ISSUE
09
P
AGES
:
7-12
OCLC
–
1121105677
Publisher:
Oscar Publishing Services
Servi
7.
Prasanthi K, Muralidhara, Rajini PS. Morphological
and biochemical perturbations in rat erythrocytes
following in vitro exposure to Fenvalerate and its
metabolite. Toxicol In Vitro. 2005;19: 449
–
456.
8.
Fraser IM, Vessel ES. Effects of metabolites of
primaquine and acetanilide on normal and glucose-
6-
phosphate
dehydrogenase-deficient
erythrocytes. J Pharm Exp Ther. 1968; 162: 155-165.
9.
Thornally PJ, Stern A, Bannister JV. A mechanism
for primaquine mediated oxidation of NADPH in
red blood cells. Biochem Pharmacol. 1983; 32: 3571-
3575.
10.
Bowman ZS , Morrow JD, Jollow D J, McMillan D. C.
Primaquine-Induced Hemolytic Anemia: Role of
Membrane Lipid Peroxidation and Cytoskeletal
Protein Alterations in the He- motoxicity of 5-
Hydroxyprimaquine. J Pharmacol Exp Ther. 2005;
314: 838
–
845.
11.
Sulekha M, Satish Y, Sunita Y, Rajesh KN.
Antioxidants: A Review. J Chem and Pharmaceu
Res. 2009; 1 :102-104
12.
Wainwright CL. Statins: is there no end to their
usefulness? Cardiovasc Res. 2005; 65:296
–
298.
13.
Liao JK. Effect of statins on 3-hydroxy-3-
methylglutaryl coenzyme A reductase inhibition
beyond low-density lipoprotein cholesterol. Am J
Cardiol. 2005; 96: 24F
–
33F.
14.
Li X, Liu C, Cui J, Dong M, Peng CH, Li QS, Cheng JL,
Jiang SL, Tian Y. Effects of pravastatin on the
function of dendritic cells in patients with coronary
heart disease. Basic Clin Pharmacol Toxicol. 2009;
104: 101
–
106.
15.
Kassan M, Montero MJ, Sevilla MA. Chronic
treatment
with
pravastatin
prevents
cardiovascular alterations produced at early
hypertensive stage. Br J Pharmacol. 2009;158: 541
–
547.
